{"id":"NCT01897233","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","officialTitle":"A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2015-10","completion":"2015-10","firstPosted":"2013-07-11","resultsPosted":"2016-12-05","lastUpdate":"2017-06-20"},"enrollment":62,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Lumacaftor","otherNames":["VX-809"]},{"type":"DRUG","name":"Ivacaftor","otherNames":["VX-770"]}],"arms":[{"label":"Lumacaftor/Ivacaftor (LUM/IVA)","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, 2-part (Part A and Part B), open-label, multicenter study to evaluate the pharmacokinetics, safety, and tolerability of lumacaftor in combination with ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the F508del-mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.","primaryOutcome":{"measure":"Part A: Observed Plasma Concentration of Lumacaftor (LUM) and Ivacaftor (IVA) at Hour 4 Post-dose (C4h) on Day 1","timeFrame":"4 hours post-morning dose on Day 1","effectByArm":[{"arm":"Part A Overall Arm: LUM/IVA","deltaMin":15200,"sd":6740}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":20,"countries":["United States","Canada"]},"refs":{"pmids":["8474788","37983082","33331662","27805836"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":5},"commonTop":["Cough","Headache","Nasal Congestion","Infective pulmonary exacerbation of cystic fibrosis","Abdominal pain upper"]}}